Pillar 1 - FTO (new thread), page-2625

I hope the new strategy provides details on how the AML, cardio and FTO opportunities become commercial in nature and at what stages do Race see as the best timing as well as what maybe the best commercial inputs/engagements for these areas (ie how far do we need to take it prior to seeking optimal licensing deal, acquisition etc). An interesting graph below from KPMG showing data of pharma deals up to 2020 albeit the data being a bit old showing licensing then strategic R&D being the most common forms of deals that occur.

How to best use our ~$18-19m of cash in bank to position our pillars for commercialisation and when to pull the trigger with BP is the multi million dollar (or billons of dollar) question!



Some of the conclusions and positions to win in the KPMG paper are below and i think Race are on point with most of these with the different pillars, de-risking activities etc.